Factbox: Roche's drug failure extends long list of Alzheimer's trial setbacks

Nov 14 (Reuters) - Roche Holding AG (ROG.S) reported on Monday that its Alzheimer's drug candidate, gantenerumab, did not meet main goals of studies, marking another setback for companies trying to find an effective treatment for the memory-robbing disease.

The results come nearly two months after partners Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) reported that their Alzheimer's disease drug, lecanemab, significantly slowed cognitive decline in a large trial.

The following is a list of high-profile Alzheimer's disease trial failures:

Reporting by Bhanvi Satija, Raghav Mahobe and Manas Mishra in Bengaluru; Editing by Bill Berkrot and Sriraj Kalluvila

Our Standards: The Thomson Reuters Trust Principles.